Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs

Listen to Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, as they answer audience questions from a live webinar about how to best use the plethora of active agents and regimens now available for patients with advanced multiple myeloma.
Paul G. Richardson, MD
Program Director
Nina Shah, MD
Peter M. Voorhees, MD
Released: August 24, 2021

In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:

  • Treatment after first relapsed
  • Optimal use of CAR T-cell therapy
  • When to use selinexor and belantamab mafodotin
  • COVID-19 vaccinations for patients with myeloma

Information on this Educational Activity

Program Director

Paul G. Richardson, MD

R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research

Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb/Celgene, Karyopharm, Oncopeptides, and Takeda and consulting fees from AstraZeneca, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio, and Takeda.

Faculty

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Nina Shah, MD, has disclosed that she has received funds for research from Bluebird Bio, Celgene/Bristol-Myers Squibb, Janssen, Nektar, Poseida, Precision Biosciences, Sutro Biopharma, and TeneoBio and consulting fees for an advisory role from Amgen, CareDx, CSL Behring, GlaxoSmithKline, Indapta Therapeutics, Karyopharm, Kite, Oncopeptides, and Sanofi.
Peter M. Voorhees, MD

Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute
Charlotte, North Carolina

Peter M. Voorhees, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Novartis, Oncopeptides, and SecuraBio and has served on the advisory board for AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Pfizer, and Sanofi.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm
Oncopeptides
Sanofi Genzyme

Related Content

Expert case-based text module on managing toxicities with BCL-2 and PI3K inhibitors in CLL, from Clinical Care Options (CCO)

Nichole Fisher Headshot Nichole Fisher, RN, BSN Nicole Lamanna, MD Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 19, 2022 Expired: May 18, 2023

Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Clinical Care Options (CCO): Expert review of key data in MDS and MPN from the 2021 ASH annual meeting

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

Clinical Care Options (CCO): Experts John M. Burke, MD, and Peter Martin, MD, review key data in lymphomas and CLL presented at the 2021 American Society of Hematology Annual Meeting

John M. Burke, MD Peter Martin, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 10, 2022 Expired: May 9, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings